- Home
- BGLC vs ACXP Comparison
BGLC vs ACXP Comparison
Compare BGLC & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- ACXP
- Stock Information
- Founded
- BGLC 2017
- ACXP 2017
- Country
- BGLC Malaysia
- ACXP United States
- Employees
- BGLC N/A
- ACXP N/A
- Industry
- BGLC Medical Specialities
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- ACXP Health Care
- Exchange
- BGLC Nasdaq
- ACXP Nasdaq
- Market Cap
- BGLC 10.4M
- ACXP 9.1M
- IPO Year
- BGLC N/A
- ACXP 2021
- Fundamental
- Price
- BGLC $5.66
- ACXP $4.15
- Analyst Decision
- BGLC
- ACXP Strong Buy
- Analyst Count
- BGLC 0
- ACXP 3
- Target Price
- BGLC N/A
- ACXP $143.67
- AVG Volume (30 Days)
- BGLC 53.1K
- ACXP 85.3K
- Earning Date
- BGLC 08-18-2025
- ACXP 08-12-2025
- Dividend Yield
- BGLC N/A
- ACXP N/A
- EPS Growth
- BGLC N/A
- ACXP N/A
- EPS
- BGLC N/A
- ACXP N/A
- Revenue
- BGLC $9,551,559.00
- ACXP N/A
- Revenue This Year
- BGLC N/A
- ACXP N/A
- Revenue Next Year
- BGLC N/A
- ACXP N/A
- P/E Ratio
- BGLC N/A
- ACXP N/A
- Revenue Growth
- BGLC 4.01
- ACXP N/A
- 52 Week Low
- BGLC $2.01
- ACXP $3.80
- 52 Week High
- BGLC $15.60
- ACXP $44.90
- Technical
- Relative Strength Index (RSI)
- BGLC 52.45
- ACXP 31.90
- Support Level
- BGLC $5.45
- ACXP $4.40
- Resistance Level
- BGLC $5.81
- ACXP $7.15
- Average True Range (ATR)
- BGLC 0.20
- ACXP 0.63
- MACD
- BGLC -0.02
- ACXP 0.09
- Stochastic Oscillator
- BGLC 77.94
- ACXP 6.24
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.